OC-0040: Risk adapted interstitial brachytherapy for breast cancer treatment: analysis of a single institution results  by Rdguez-Ibarria, N. et al.
3rd ESTRO Forum 2015              S19 
Center, Radiation Oncology, Rotterdam, The Netherlands 
2Erasmus Medical Center Rotterdam Daniel den Hoed Cancer 
Center, Urology, Rotterdam, The Netherlands  
Purpose/Objective 
Background:  
Bladder preservation combining surgery and radiotherapy 
could maintain quality of life without compromising tumor 
control in selected patients with bladder carcinoma. Several 
reports confirm good results. Prognosis of patients presented 
with recurrence after primary treatment with this regimen is 
not well known. 
We report the long term results of treated recurrences after 
bladder preservation treatment with brachytherapy. 
Materials and Methods: Between 1989 and 2011, 192 
selected patients with muscle-invasive bladder cancer were 
treated with a combined regimen of preoperative external 
radiotherapy, and subsequent surgical exploration with or 
without partial cystectomy and interstitial brachytherapy. 
Data of patients presenting with local recurrence after this 
regimen were retrospectively collected. The primary end 
points were local recurrence-free survival (LRFS) and overall 
survival (OS) (after the treatment of recurrence). 
Complications of the secondary treatment were reported. 
Results: The median follow-up after primary treatment was 
105 months (6-212 months). In 40/192 (20.8%) patients a 
local recurrence was detected. Four patients were excluded 
because of lack of data.  
Treatment of the local recurrence was performed in 28/36 
(78%) patients. For 18 patients a salvage cystectomy was 
performed; 10 patients were treated with transurethral 
resection followed by intravesical BCG. In 4 patients 
cystectomy procedures were discontinued. 
The local recurrence was muscle invasive in 19 patients; 
mostly treated by salvage cystectomy (14/19). The LRFS after 
the treatment of recurrence was 70% and 55% after 2 and 5 
years, respectively. The OS 2 and 5 years after treatment was 
71% and 34%, respectively. The LRFS of the 18 patients 
treated with salvage cystectomy 71% after 2 years as well 5 
years and the OS was 67% and 36% after 2 and 5 years, 
respectively. 
In 11/18 (61%) patients treated with cystectomy, surgical 
complications were reported, 6/11 patients with Clavien 
Dindo complications grade ≥ 3.  
Conclusions: The LRFS of patients treated for local 
recurrence after bladder-sparing regimen using 
brachytherapy offers good long-term oncological outcome. 
Salvage cystectomy gave the best long term local control, 
unfortunately with more surgical complications.  
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Purpose/Objective: Interstitial multicatheter brachytherapy 
is the most frequently used technique of partial breast 
irradiation, and could be used to deliver surgical bed boost 
and moreover exclusively accelerated partial breast 
irradiation (APBI). Our purpose is to evaluate our clinical 
results using both options of high dose rate (HDR) 
brachytherapy, in a risk adapted way.  
Materials and Methods: Between 1999 and 2014, 276 breast 
cancer patients has been treated with brachytherapy in our 
institution, with a mean follow-up of 65 months. It has been 
used as a boost combined with external beam radiotherapy 
(EBRT) in 125 patients with a median dose of 8 Gy in 
tumorectomy bed added to conventional doses of EBRT (50 
Gy). In the others 151 patients it has been delivered as 
exclusive APBI, with a dose of 32 Gy separated in 8 fractions 
of 4 Gy. ASTRO and GEC-ESTRO APBI recommendations has 
been registered for every patient.  
Results: The mean age at diagnosis was 61.67 years (range: 
24-92), 80.4% presented a postmenopausal status, in 82% 
tumor size was < 2 cm, 47 % grade I, 35% grade II and 13% 
grade III. Using APBI GEC-ESTRO recommendations, patients 
were classified as low risk in 41%, intermediate risk 21% and 
high risk 38%. For the ASTRO criteria, patients were classified 
as suitable 31%, cautionary 37% and unsuitable 32%. Most 
intermediate and high risk patients treated with APBI were 
elder than 70 years or they lived far from our institution. 
With a mean follow-up of 65 months (range: 4-179), actuarial 
local disease free survival was 98.1% at 5 years and 94.1% at 
10 years. Actuarial cause specific survival was 96.8% at 5 
years and 94.2% at 10 years. Five years and 10 years actuarial 
overall survival were 90.1% and 85.7% respectively.  
For the whole group, the best risk fit was obtained using 
GEC-ESTRO recommendations for APBI, with a local disease 
free survival at 5 and 10 years of 100% for those patients with 
low risk of recurrence. 
Conclusions: HDR risk adapted brachytherapy represents a 
good approach in breast cancer conservative treatment in 
terms of local control and survival. GEC-ESTRO 
recommendations has demonstrated to be a good tool to 
select patients treatment option. 
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Purpose/Objective: To investigate the outcome after PBI 
with 192Ir interstitial HDR brachytherapy in patients with early 
breast cancer. 
Materials and Methods: From August 2003 to May 2014 260 
patients aged 42-85 years (median 67) were enrolled. There 
were 237 infiltrating tumors and 23 DCIS (median tumor size 
9 mm, range 1.25-28) ER and PgR were positive in 236 and 
210 cases respectively. Axillary nodes were negative in 257 
patients; 3 patients had the sentinel positive node, 1 with 
micrometastasis. 29 patients received adjuvant 
chemotherapy, 221 hormonal therapy. Treatment schedule 
was 4 Gy twice a day for 4 days, up to a total dose of 32 Gy 
with an interval between fractions of at least 6 hours. 
Survival was analyzed by Kaplan-Meier estimator. Cosmetic 
results were evaluated, using the Harvard criteria, by 
radiation oncologists and patients, Cohen's k-test of inter-
rater agreement (k-value ranging from 0 to 1) estimated 
concordance between patients and physicians.  
Results: Median follow-up was 74 months (range 2-128). Four 
local relapses (1.5%) were observed 12, 24, 48, 96 months 
after PBI. One regional relapse was observed in the 
